Xiaofei Xu

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 6

Top Venues

Cancers

OncoTargets and therapy

Wenzhou Medical University (BSC)

This page only lists publications with an associated author ORCID identifier.

Education History

Wenzhou Medical University Sep 01 2014 - Jul 05 2019

China

BSC

Publications

Shiwei Hu, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, Jian Huang
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Cancers 14 (23) (2022)
Shiwei Hu, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, Jian Huang
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Cancers 14 (23) (2022)
Shiwei Hu, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, Jian Huang
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Cancers 14 (23) (2022)
Shiwei Hu, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, Jian Huang
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Cancers 14 (23) (2022)
Shiwei Hu, Dan Chen, Xiaofei Xu, Lan Zhang, Shengjie Wang, Keyi Jin, Yan Zheng, Xiaoqiong Zhu, Jie Jin, Jian Huang
Targeted Next-Generation Sequencing Identifies Additional Mutations Other than BCR∷ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study. Cancers 14 (23) (2022)
Shuna Luo, Xiaofei Xu, Xingnong Ye, Xiaoqiong Zhu, Cai Wu, Dan Chen, Jingxia Jin, Yan Zheng, Mengli Zheng, Jian Huang
Ruxolitinib Plus Decitabine Effectively Treats Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, by Decreasing the Variant Allele Frequency of KRAS. OncoTargets and therapy 13 (2020)

Xiaofei Xu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Xiaofei Xu